Atorvastatin calcium/choline fenofibrate

阿托伐他汀钙/非诺贝特胆碱

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAtorvastatin calcium/choline fenofibrate
Drug Alias NameAtorvastatin calcium trihydrate+choline fenofibrate非诺贝特胆碱/阿托伐他汀钙Atorvastatin+Choline Fenofibrate非诺贝特胆碱+阿托伐他汀钙阿托伐他汀钙+非诺贝特胆碱 +[9] 
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor αHMG-CoA reductase
Therapy Area/IndicationsDyslipidemias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsYes Choline FenofibrateAtorvastatin Calcium Hydrate
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesChong Kun Dang Pharmaceutical Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVeloxis PharmaceuticalsChong Kun Dang Pharmaceutical Corp
Active IndicationsN/A
Inactive IndicationsDyslipidemias

Other Information

ATC CodeN/A
Related LinksN/A